Literature DB >> 8121865

Control of plasma glucose with somatostatin analogue (SMS 201-995) during surgical removal of insulinomas.

C Utas1, F Kelestimur, A Boyaci, A Saglam.   

Abstract

Prevention of hypoglycaemia may sometimes be difficult in the operative period of insulinoma when parenteral volume overload is contraindicated due to severe cardiac failure. We investigated the effects of octreotide on hypoglycaemia during operations in two patients with insulinoma, one of whom had severe congestive heart failure. We found no hypoglycaemic values by using octreotide 100 micrograms administered subcutaneously one hour before surgery. Octreotide therapy can safely be used before surgery to prevent hypoglycaemia in patients with insulinoma.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8121865      PMCID： PMC2400022          DOI： 10.1136/pgmj.69.818.920

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  6 in total

1.  On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma.

Authors:  L Verschoor; P Uitterlinden; S W Lamberts; E Del Pozo
Journal:  Clin Endocrinol (Oxf)       Date:  1986-11       Impact factor: 3.478

2.  Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones.

Authors:  K Osei; T M O'Dorisio
Journal:  Ann Intern Med       Date:  1985-08       Impact factor: 25.391

Review 3.  Clinical review 42: Hypoglycemias.

Authors:  F J Service
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

4.  Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor.

Authors:  L De Marinis; A Barbarino
Journal:  Metabolism       Date:  1980-07       Impact factor: 8.694

5.  Continuous monitoring and control of plasma glucose during operation for removal of insulinomas.

Authors:  S S Schwartz; D L Horwitz; B Zehfus; B G Langer; E Kaplan
Journal:  Surgery       Date:  1979-06       Impact factor: 3.982

6.  Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug?

Authors:  C D Stehouwer; W F Lems; H R Fischer; W H Hackeng
Journal:  Neth J Med       Date:  1989-08       Impact factor: 1.422
  6 in total
  1 in total

1.  The effects of octreotide in a patient with Nelson's syndrome.

Authors:  F Kelestimur; C Utas; O Ozbakir; A Selçuklu; O Kandemir; N Ozcan
Journal:  Postgrad Med J       Date:  1996-01       Impact factor: 2.401
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.